Allurion shares surge 27.43% after-hours as study shows 23% weight loss and 14% lean mass gain with low-dose tirzepatide combo.

Allurion Technologies Inc. surged 27.43% in after-hours trading following the announcement of positive clinical results from a combination therapy involving its Smart Capsule and low-dose tirzepatide. The study showed an average 23% total body weight loss and a 14% increase in lean body mass over 12 months, with all patients maintaining adherence to tirzepatide at significantly lower doses than standard regimens. These results address key limitations of GLP-1 therapies, such as muscle wasting and poor adherence, positioning Allurion’s program as a complementary solution. The data, presented as a case series, highlights the potential for improved long-term weight management and metabolic outcomes, aligning with the stock’s sharp post-announcement rally.